Citations 2
Real‐World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma ( RRMM ): An International Myeloma Working Group Immunotherapy Registry Real‐World Analysis
Janakiram, Murali , Tan, C. R., Mian, Hira, Huang, C Y, Popat, Rakesh , Martínez‐Lopez, Joaquín, Kastritis, Efsthathios, Chng, Wee-Joo, Kapoor, Prashant , Dave, Mrugakshi, Bal, Susan, Garderet, Laurent, Corraes, Andre De Menezes Silva , Riedhammer, Christine , Steinbrunn, Torsten, Nagarajan, Chandramouli, Einsele, Hermann, Martin, T, Krishnan, Amrita, Lin, Yi, Martínez‐López, Joaquín , Frigault, Matthew J. , Larrea, Carlos Fernández de , Mian, Hira , Tan, Carlyn R , Kastritis, Efstathios , Corona, Magdalene , Martinez-Lopez, Joaquin , Mian, Hira , Janakiram, Murali , Tan, Carlyn , Popat, Rakesh , Chng, Wee Joo , Bal, Susan , Garderet, Laurent , Steinbrunn, Torsten , Nagarajan, Chandramouli
American Journal of Hematology | May 20, 2026 | Volume: 101 | Issue: 8 | Pages: 1928-1937
ABSTRACT Talquetamab is a GPRC5D × CD3 bispecific antibody approved for relapsed/refractory multiple myeloma (RRMM). This is the first real‐world study to comprehensively report muco‐cutaneous toxicities, infections, and efficacy of talquetamab in 151 patients across five countries with the longest follow‐up reported enabling better efficacy and toxicity estimates. The median age was 64 years; high‐risk cytogenetics were present in 42%; ECOG ≥ 2 in 22%; 12% had creatinine clearance < 30; and 55% would not have met MonumenTAL‐1 eligibility. Patients received a median of 6 prior lines of therapy, 53% were penta‐refractory, and 75% received prior BCMA therapy. Talquetamab was associated with skin toxicity in 39.7%, nail toxicity in 75.5%, dysgeusia in 60.4%, and oral toxicities in 62.9%, with grade ≥ 3 events uncommon (≤ 4%) and dose interruptions infrequent (9.6% for skin toxicity, 6.9% for dysgeusia, and 4.0% for oral toxicities). These findings underscore the need for improved supportive care for muco‐cutaneous toxicities. In multivariate analysis, only platelet count < 50 (HR 1.8, 95% CI 1.15–2.83) was associated with inferior PFS, while penta‐refractory status, absolute lymphocyte count < 0.4, and prior BCMA‐targeted therapy were not statistically significant. With a median follow‐up of 12.7 months, the overall response rate was 67.6%, median progression‐free survival was 7 months, and 12‐month overall survival was 65%. This study shows that talquetamab efficacy is maintained in a heavily pretreated real‐world population with high prior BCMA exposure and notable comorbidity burden.
Early mortality with bispecific antibody therapy in RRMM: an IMWG immunotherapy database real-world analysis
Tan, Carlyn Rose, Usmani, Saad Z., Derkach, Andriy , Corraes, Andre De Menezes Silva, Parrondo, Ricardo , Ailawadhi, S., Asoori, Sireesha, Dave, Mrugakshi, Popat, Rakesh, Morjaria, Oliver, Hajek, Roman , Htut, Myo , Kastritis, Efstathios, Dimopoulos, M A, Martínez-López, Joaquín, Nagarajan, Chandramouli, Bal, Susan, Costa, Luciano J., Einsele, Hermann, Steinbrunn, Torsten, Riedhammer, Christine , Banerjee, Rahul, Chng, Wee Joo, Tso, Allison CY, Lin, Yi, Martin, Tom, Mian, Hira, Martínez‐López, Joaquín , Mian, Hira , Tan, Carlyn R , de Meneze Silva Corraes, Andre, Mihalyova, Jana , Visram, Alissa , Kastritis, Efstathios , Martinez-Lopez, Joaquin , Nagarajan, Chandramouli , Bal, Susan , Costa, Luciano J , Waldschmidt, Johannes M , Banerjee, Rahul , Tso, Allison , Martin, Thomas , Mian, Hira , Parrondo, Ricardo D , Derkach, Andriy , Usmani, Saad Z. , Corraes, Andre De Menezes Silva , Ailawadhi, Sikander , Popat, Rakesh , Hájek, Roman , Janakiram, Murali , Visram, Alissa , Kastritis, Efstathios , Dimopoulos, Meletios Α. , Nagarajan, Chandramouli , Bal, Susan , Costa, Luciano J. , Steinbrunn, Torsten , Banerjee, Rahul , Chng, Wee Joo
Blood Advances | February 24, 2026 | Volume: 10 | Issue: 9 | Pages: 2937-2946
10.1182/bloodadvances.2025019231
Abstract Recent therapeutic advances, including bispecific antibodies (bsAbs), have improved outcomes for patients with relapsed/refractory multiple myeloma (RRMM). However, early mortality (EM) remains a significant challenge, even in the era of novel immunotherapies. We conducted a multicenter, retrospective analysis of real-world patients with RRMM treated with commercial bsAbs to evaluate the incidence and causes of EM. Between May 2022 and June 2025, a total of 441 patients were treated across 7 countries. EM, defined as death within 12 months of therapy initiation, occurred in 148 patients (34%), with a median time from bsAb initiation to death of 2.87 months (interquartile range, 1.38-6.85). The leading cause of EM was progressive disease (72%), followed by infection (13%); regardless of the cause of death, 82% had active disease at the time of death. Our findings highlight that despite encouraging efficacy, EM remains high among real-world bsAb recipients, emphasizing the need for improved disease control strategies and supportive care interventions.